Skip to main content
. 2020 Jun 4;11:2817. doi: 10.1038/s41467-020-16309-2

Fig. 8. ARS-1620, a G12C-specific inhibitor, disrupts the KRASG12C-AGO2 interaction.

Fig. 8

IP of endogenous AGO2 followed by immunoblot to detect KRAS in KRASG12C harboring (a) H358 and (b) MIA PaCa-2 cells treated with varying concentrations of ARS-1620 for three and nine hours, respectively. KRASG12D harboring (c) Panc 05.04 and (d) Panc 10.05 cells, respectively, treated with ARS-1620 for 24 h followed by AGO2 IP and immunoblot analysis of KRASG12D. For each cell line, input blots for AGO2 and RAS are shown.